Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease.
Twenty-two patients with advanced Parkinson's disease whose symptom fluctuations had initially responded to deprenyl supplementation were followed for 19 to 27 months on that drug. The improvement disappeared in most cases after a mean of 7-8 months but persists at latest follow-up in 5 patients. Transient or continuing abnormalities in liver function tests occurred in 9 patients.
Golbe
L I
LI
Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick 08903.
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D004796:Clinical Enzyme Tests; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000008:administration & dosage*; D012449:Safety; D012642:Selegiline / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors
D010627:Phenethylamines; D012642:Selegiline